Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with ovarian cancer.Hatice Güngör, Hani Gabra, Agnieszka Michael et al.|Journal of Clinical Oncology|2011Cited by 14
Mutation and Protein Expression Biomarkers Correlate with Response to AKT Inhibition in a Phase I Trial of the Oral Pan AKT Inhibitor GSK2141795 (GSK795) in Patients (pts) with Platinum Resistant Ovarian CancerH. Gunqor, Hani Gabra, Euan A. Stronach et al.|European Journal of Cancer|2011Cited by 1